K2M 10-Q 4 Aug 15 2015 Q2 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION DOCUMENT AND ENTITY INFORMATION - shares	6 Months Ended
	Jun. 30, 2015	Jul. 22, 2015
Entity [Abstract]
Entity Registrant Name	K2M Group Holdings, Inc.
Entity Central Index Key	1,499,807
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		41,337,632

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 28,787	$ 11,411
Accounts receivable, net	41,327	33,937
Inventory, net	55,686	52,617
Deferred income taxes	2,313	3,437
Prepaid expenses and other current assets	11,489	3,911
Total current assets	139,602	105,313
Property and equipment, net	4,822	4,220
Goodwill and intangible assets, net	158,637	163,423
Other assets, net	22,975	29,672
Total assets	326,036	302,628
Current liabilities:
Accounts payable	17,456	14,018
Accrued expenses	11,056	10,077
Accrued payroll liabilities	9,939	11,488
Total current liabilities	38,451	35,583
Deferred income taxes	7,356	8,479
Other liabilities	858	112
Total liabilities	$ 46,665	$ 44,174
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value, 750,000,000 shares authorized; 40,290,124 and 37,366,098 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	$ 40	$ 37
Additional paid-in capital	426,546	386,795
Accumulated other comprehensive income	3,497	1,827
Accumulated deficit	(150,712)	(130,205)
Total stockholders’ equity	279,371	258,454
Total liabilities and stockholders’ equity	$ 326,036	$ 302,628

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value per share (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	750,000,000	750,000,000
Common stock, shares issued (in shares)	40,290,124	37,366,098
Common stock, shares outstanding (in shares)	40,290,124	37,366,098

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue	$ 56,354	$ 47,488	$ 106,778	$ 89,739
Cost of revenue	18,620	16,034	36,117	30,448
Gross profit	37,734	31,454	70,661	59,291
Operating expenses:
Research, development and engineering	5,021	3,785	9,654	6,982
Sales and marketing	27,770	23,721	52,780	46,169
General and administrative	13,579	16,761	26,908	32,651
Total operating expenses	46,370	44,267	89,342	85,802
Loss from operations	(8,636)	(12,813)	(18,681)	(26,511)
Other income (expense):
Foreign currency transaction gain (loss)	2,597	728	(1,540)	950
Related Party Discount on Prepayment of Debt	0	(4,825)	0	(4,825)
Interest expense	(164)	(752)	(244)	(1,999)
Total other income (expense), net	2,433	(4,849)	(1,784)	(5,874)
Loss before income tax expense	(6,203)	(17,662)	(20,465)	(32,385)
Income tax expense	19	21	42	45
Net loss	(6,222)	(17,683)	(20,507)	(32,430)
Accretion and adjustment of preferred stock to fair value		8,059		6,879
Accretion and adjustment of preferred stock to fair value	0		0
Net loss attributable to stockholders	$ (6,222)	$ (9,624)	$ (20,507)	$ (25,551)
Net loss per share attributable to common stockholders:
Basic and diluted (in dollars per share)	$ (0.16)	$ (0.32)	$ (0.52)	$ (0.96)
Weighted average shares outstanding:
Basic and diluted (in shares)	39,836,509	30,441,034	39,291,183	26,504,068

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net loss	$ (6,222)	$ (17,683)	$ (20,507)	$ (32,430)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(976)	(184)	1,670	(270)
Other comprehensive (loss) income	(976)	(184)	1,670	(270)
Comprehensive loss	$ (7,198)	$ (17,867)	$ (18,837)	$ (32,700)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	IPO [Member]	IPO [Member]Common Stock [Member]	IPO [Member]Additional Paid-in Capital [Member]
Beginning Balance (in shares) at Dec. 31, 2014	37,366,098	37,366,098
Beginning Balance at Dec. 31, 2014	$ 258,454	$ 37	$ 386,795	$ 1,827	$ (130,205)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(20,507)				(20,507)
Other comprehensive income	1,670			1,670
Stock-based compensation	$ 3,909		3,909
Issuances of common stock (in shares)							2,044,990
Issuances of common stock						$ 35,434	$ 2	$ 35,432
Exercise of options (in shares)	746,572	879,036
Issuances and exercise of stock-based compensation benefit plans, net of income tax	$ 411	$ 1	410
Ending Balance (in shares) at Jun. 30, 2015	40,290,124	40,290,124
Ending Balance at Jun. 30, 2015	$ 279,371	$ 40	$ 426,546	$ 3,497	$ (150,712)

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net loss	$ (20,507)	$ (32,430)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	12,270	19,604
Provision for allowance for doubtful accounts	258	299
Provision for inventory allowances	875	1,048
Stock-based compensation	3,909	1,758
Amortization of issuance and discount costs included in interest expense	0	4,928
Changes in operating assets and liabilities:
Accounts receivable	(7,207)	(1,908)
Inventory	(933)	(13,843)
Prepaid expenses and other assets	(4,089)	(2,582)
Accounts payable, accrued expenses, and accrued payroll liabilities	3,089	3,970
Net cash used in operating activities	(12,335)	(19,156)
Investing activities
Purchase of surgical instruments	(4,375)	(7,338)
Purchase of property and equipment	(1,691)	(1,087)
Purchase of intangible assets	(388)	(19)
Net cash used in investing activities	(6,454)	(8,444)
Financing activities
Borrowings on bank line of credit	25,000	0
Repayments on bank line of credit	(25,000)	(23,500)
Proceeds from issuances of notes to stockholders	0	14,634
Prepayment of notes to stockholders	0	(39,212)
Payment of dividends on Series A and Series B redeemable convertible preferred stock	0	(18,547)
Proceeds from issuances of common stock, net of issuance costs	35,927	123,456
Issuances and exercise of stock-based compensation benefit plans, net of income tax	411	(475)
Net cash provided by financing activities	36,338	56,356
Effect of exchange rate changes on cash and cash equivalents	(173)	50
Net increase in cash and cash equivalents	17,376	28,806
Cash and cash equivalents at beginning of period	11,411	7,419
Cash and cash equivalents at end of period	28,787	36,225
Significant noncash financing activities
Adjustment of preferred stock to fair value	0	(8,059)
Deferred offering costs	493	2,298
Cash paid for:
Income taxes	33	34
Interest	68	1,716
Series A Redeemable Convertible Preferred Stock [Member]
Significant noncash financing activities
Accretion of redeemable convertible preferred stock	0	1,195
Series B Redeemable Convertible Preferred Stock [Member]
Significant noncash financing activities
Accretion of redeemable convertible preferred stock	$ 0	$ (15)

GENERAL AND SUMMARY OF SIGNIFIC

GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES In this Quarterly Report on Form 10-Q, unless the context otherwise requires, references to "K2M," "the Company,” "we," “us” and "our," refer to K2M Group Holdings, Inc. together with its consolidated subsidiaries. K2M Group Holdings, Inc. was formed as a Delaware corporation on June 29, 2010. On July 2, 2010, K2M, Inc., a company initially incorporated in 2004, entered into an Agreement and Plan of Merger (the Merger Agreement) with Altitude Group Holdings, Inc. (Altitude) and Altitude Merger Sub, Inc. (Merger Sub). Altitude was a newly formed corporation and an indirect wholly-owned subsidiary of Welsh, Carson, Anderson & Stowe XI, L.P. On August 12, 2010 (the Merger Date), upon the closing of the transactions under the Merger Agreement, Merger Sub merged with and into K2M with K2M being the surviving corporation of such merger (the Merger) and Altitude was renamed K2M Group Holdings, Inc. We are a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine technologies and techniques. Our complex spine products are used by spine surgeons to treat some of the most difficult and challenging spinal pathologies, such as deformity (primarily scoliosis), trauma, and tumor. We have applied our product development expertise in innovating complex spine technologies and techniques to the design, development, and commercialization of an expanding number of proprietary Minimally Invasive surgery, or MIS products. Our MIS products are designed to allow for less invasive access to the spine and faster patient recovery times as compared to traditional open access surgical approaches for both complex spine and degenerative spine pathologies. We have leveraged these core competencies in the design, development and commercialization of an increasing number of products for patients suffering from degenerative spinal conditions. Unaudited Interim Results The accompanying condensed consolidated balance sheets as of June 30, 2015 and December 31, 2014 , the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2015 and 2014 , the condensed consolidated statements of changes in stockholders’ equity as of June 30, 2015 , and the condensed consolidated statements of cash flows for the six months ended June 30, 2015 and 2014 are unaudited. The unaudited interim financial statements have been prepared on the same basis of accounting as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly our financial position and results of operations and cash flows for the periods presented. The results for the three and six months ended June 30, 2015 are not necessarily indicative of future results. All information as of June 30, 2015 and for the three and six month periods ending June 30, 2015 and 2014 within these notes to the condensed consolidated financial statements is unaudited. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States or US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Net Loss per Share Basic net loss per common share is determined by dividing the net loss allocable to common stockholders by the weighted average number of common shares outstanding during the periods presented, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the net loss allocable to common stockholders by the weighted average number of shares of common stock and common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of our stock option grants and the if-converted method is used to determine the dilutive effect of our Series A redeemable convertible preferred stock or Series A Preferred and Series B redeemable convertible preferred stock or Series B Preferred, until their conversion into common stock in May 2014. The weighted average shares used to calculate both basic and diluted loss per share are the same because common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive. Foreign Currency Translation and Other Comprehensive Loss The account balances of foreign subsidiaries are translated into U.S. dollars using exchange rates for assets and liabilities at the balance sheet date and average prevailing exchange rates for the period for revenue and expense accounts. Adjustments resulting from translation are included in other comprehensive income (loss), which is our only component of accumulated other comprehensive loss. Remeasurement gains and losses from foreign currency transactions are included in the consolidated statements of operations in the period in which they occur. Issuance of Common Stock On February 2, 2015, we completed a second public offering of 6,044,990 shares of our common stock at a price of $ 18.75 per share. We sold 2,044,990 shares of common stock in the offering and selling stockholders sold 4,000,000 shares of common stock in the offering. We received net proceeds from the offering of approximately $ 35,400 after deducting the underwriting discount and offering expenses. We expect to use proceeds of the primary portion of the offering for working capital and general corporate purposes which is expected to include the expansion of our global distribution network and the purchase of inventory to support sales efforts. Use of proceeds may also include the acquisition of or investment in complementary products, technologies or businesses. The principal purposes of the secondary offering were to facilitate an orderly distribution of shares by the selling stockholders and to increase the public float of our shares. We did not receive any proceeds from shares of common stock sold by the selling stockholders. In connection with the offering, certain of the selling stockholders granted the underwriters an option to purchase from them additional shares of common stock at the public offering price, less underwriting discounts. On February 12, 2015, the underwriters exercised this option and purchased 906,748 shares of common stock from the selling stockholders at a price of $ 18.75 per share before underwriting discounts. We did not receive any proceeds from the sale of these shares. Please refer to Note 14, Subsequent Events , for share issuances subsequent to June 30, 2015. Recent Accounting Pronouncements We qualify as an “emerging growth company” (EGC) pursuant to the provisions of the JOBS Act and elected to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act which permits EGCs to defer compliance with new or revised accounting standards (the EGC extension) until non-issuers are required to comply with such standards. Accordingly, so long as we continue to qualify as an EGC, we will not have to adopt or comply with new accounting standards until non-issuers are required to comply with such standards. In May 2014, the Financial Accounting Standards Board, or FASB amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In July 2015, the FASB confirmed the deferral of the effective date by one year for public entities, other than EGCs that have elected the EGC extension. The guidance will now be effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted for reporting periods beginning after December 15, 2016. EGCs that have elected the EGC extension, including us, and non-public entities will be required to comply with the guidance for annual reporting periods beginning after December 15, 2018. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of the initial application. We are evaluating the impact of these amendments and the transition alternatives on our consolidated financial statements. In April 2015, the FASB issued guidance to simplify the presentation of debt issuance costs by requiring them to be presented as a deduction from the corresponding debt liability, rather than reported as an asset. This will make the presentation of debt issuance costs consistent with the presentation of debt discounts and premiums. This new guidance affects only the presentation of debt issuance costs, not recognition and measurement. For public entities other than EGCs that have elected the EGC extension, the guidance will be effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. For all other entities, EGCs that have elected the EGC extension, including us, and non-public entities will be required to comply with the guidance on a retrospective basis for fiscal years beginning after December 15, 2015, and interim periods within the fiscal years beginning after December 15, 2016. Although adoption of this new guidance may impact how such items are classified on our balance sheet, we do not anticipate that the adoption of this guidance will have a material impact on our financial position, results of operations or cash flows. There will be no changes to the presentations of our other consolidated financial statements. In July 2015, the FASB issued authoritative guidance to simplify the subsequent measurement of inventory. Under this new standard, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public entities other than EGCs that have elected the EGC extension, the guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. For all other entities, EGCs that have elected the EGC extension, including us, and non-public entities will be required to comply with the guidance for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of this guidance.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
ACCOUNTS RECEIVABLE	ACCOUNTS RECEIVABLE The following table summarizes the accounts receivables, net of allowances: June 30, December 31, Accounts receivable $ 44,046 $ 36,431 Allowances (2,719 ) (2,494 ) Accounts receivable, net $ 41,327 $ 33,937

INVENTORY

INVENTORY	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY The following table summarizes the inventory, net of allowance: June 30, December 31, Finished goods $ 82,767 $ 78,331 Inventory allowances (27,081 ) (25,714 ) Inventory, net $ 55,686 $ 52,617 Inventory includes surgical instruments available for sale with a carrying value of $ 8,401 and $ 8,491 at June 30, 2015 and December 31, 2014 , respectively.

PREPAID AND OTHER CURRENT ASSET

PREPAID AND OTHER CURRENT ASSETS (Notes)	6 Months Ended
	Jun. 30, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAIDS AND OTHER CURRENT ASSETS	PREPAID EXPENSES AND OTHER CURRENT ASSETS The following table summarizes prepaid expenses and other current assets: June 30, December 31, Restricted cash $ 6,669 $ — Prepaid expenses 2,753 2,385 Other 2,067 1,526 Total $ 11,489 $ 3,911 As of June 30, 2015 , restricted cash consisted of amounts held in escrow for tenant improvement costs for our new corporate headquarters.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill and intangible assets comprise the following: June 30, 2015 Estimated Useful Lives Gross Accumulated Amortization Net Goodwill — $ 121,814 $ — $ 121,814 Indefinite-lived intangible assets: Trademarks — 12,900 — 12,900 In-process research and development — 900 — 900 Other — 278 — 278 Subtotal 14,078 — 14,078 Subject to amortization Developed technology 4 - 6 years 62,000 (49,351 ) 12,649 Licensed technology 4 - 6 years 52,600 (52,250 ) 350 Customer relationships 4 - 7 years 29,700 (20,684 ) 9,016 Patents and other 2 - 17 years 1,801 (1,071 ) 730 Subtotal 146,101 (123,356 ) 22,745 Total $ 281,993 $ (123,356 ) $ 158,637 December 31, 2014 Estimated Useful Lives Gross Accumulated Amortization Net Goodwill — $ 121,814 $ — $ 121,814 Indefinite-lived intangible assets: Trademarks — 12,900 — 12,900 In-process research and development — 900 — 900 Other — 278 — 278 Subtotal 14,078 — 14,078 Subject to amortization Developed technology 4 - 6 years 62,000 (46,460 ) 15,540 Licensed technology 4 - 6 years 52,600 (52,175 ) 425 Customer relationships 4 - 7 years 29,700 (18,563 ) 11,137 Patents and other 2 - 17 years 1,414 (985 ) 429 Subtotal 145,714 (118,183 ) 27,531 Total $ 281,606 $ (118,183 ) $ 163,423 Amortization expense was $ 2,551 and $ 7,541 for the three months ended June 30, 2015 and 2014 , respectively, and $ 5,173 and $ 15,092 for the six months ended June 30, 2015 and 2014 , respectively. As of June 30, 2015 , the expected amortization expense for the remainder of 2015 and the following four years and thereafter is as follows: June 30, 2015 2015 $ 5,119 2016 10,238 2017 6,624 2018 129 2019 and thereafter 635 Total $ 22,745

OTHER ASSETS

OTHER ASSETS	6 Months Ended
	Jun. 30, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER ASSETS	OTHER ASSETS Other assets consist of the following: June 30, December 31, Surgical instruments, net $ 21,193 $ 21,392 Restricted cash 1,320 8,114 Other 462 166 Total $ 22,975 $ 29,672 Surgical instruments are stated net of accumulated amortization of $ 23,118 and $ 18,610 at June 30, 2015 and December 31, 2014 , respectively. Amortization expense was $ 2,229 and $ 1,464 for the three months ended June 30, 2015 and 2014 , respectively, and $ 4,384 and $ 2,772 for the six months ended June 30, 2015 and 2014 , respectively. As of December 31, 2014 , restricted cash included amounts placed in escrow for tenant improvement costs of approximately $ 6,700 for our new corporate headquarters. These amounts included as restricted cash were reclassed to prepaid expenses and other current assets as of June 30, 2015 , because we believe such tenant improvements will be incurred by June 30, 2016. Restricted cash also includes deposits made on pending bids or contracts with customers of $ 1,320 and $ 1,447 as of June 30, 2015 and December 31, 2014 , respectively.

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	ACCRUED EXPENSES Accrued expenses consist of the following: June 30, December 31, Accrued commissions $ 5,712 $ 4,942 Accrued royalties 2,261 2,464 Other 3,083 2,671 Total $ 11,056 $ 10,077

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION We have four stock-based compensation plans including the 2014 Employee Omnibus Incentive Plan (Omnibus Incentive Plan), the 2014 Employee Stock Purchase Plan (ESPP), the 2010 Equity Award Plan and the 2010 Independent Agent Plan, collectively, “the Plans”. The purpose of the Plans are to provide incentives to employees, directors, agents and advisors. The Plans are administered by our board of directors or their delegates. The number, type of equity incentive, exercise or share purchase price, and vesting terms are determined in accordance with the Plans, as applicable. As of June 30, 2015 , there was a total of 1,374,208 shares of common stock available for future grants under the plans. Stock-based compensation expense by financial statement line item, employees and non-employees and type of award for the respective period follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Cost of revenue $ 159 $ 105 $ 317 $ 111 Research, development, and engineering 151 121 300 143 Sales and marketing 753 436 1,471 633 General and administrative 945 720 1,821 871 $ 2,008 $ 1,382 $ 3,909 $ 1,758 Employees $ 1,904 $ 1,467 $ 3,731 $ 1,737 Non-employees 104 (85 ) 178 21 Total $ 2,008 $ 1,382 $ 3,909 $ 1,758 Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock options $ 573 $ 385 $ 1,110 $ 761 Restricted stock units (RSUs) 1,372 968 2,669 968 ESPP 63 29 130 29 Total $ 2,008 $ 1,382 $ 3,909 $ 1,758 A summary of stock option plans activity during the six months ended June 30, 2015 is as follows: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2014 4,277,229 $ 9.55 5.83 $ 48,418 Granted 88,151 21.56 Exercised (746,572 ) 7.28 Expired (2,885 ) 5.13 Forfeited (39,259 ) 13.09 Outstanding at June 30, 2015 (2) 3,576,664 $ 10.28 5.98 $ 49,128 Vested or expected to vest: At June 30, 2015 (3) 3,246,834 $ 10.09 5.89 $ 45,221 Vested: At June 30, 2015 1,836,501 $ 9.10 4.98 $ 41,440 (1) Calculated using the estimated per-share fair market value of our common stock on June 30, 2015 and December 31, 2014 , which was $ 24.02 , and $ 20.87 , respectively. (2) The total includes 995,995 unvested performance-based options at June 30, 2015 . (3) Outstanding options, net of forfeiture rate. Restricted Stock Units A summary of RSU activity during the six months ended June 30, 2015 is as follows: Unvested RSUs Unvested at December 31, 2014 765,023 Vested (351,022 ) Unvested at June 30, 2015 414,001 All the RSUs which vested in 2015 were net settled, which resulted in the forfeiture of 155,494 units in lieu of withholding taxes during the six months ended June 30, 2015 .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES On December 11, 2014, we entered into a Deed of Lease (the “Lease Agreement”) with TC Oaklawn Owner, LLC (the “Landlord”) with respect to our new corporate headquarters to be located in two adjacent buildings in Leesburg, Virginia (the “Buildings”). On March 13, 2015 we received $ 790 of cash grant incentives from several government originators, which were included in cash and cash equivalents. There are no restrictions on the use of the cash proceeds. Pursuant to the grant agreements, we or the Landlord are required to make certain investments in the Buildings and we are required to increase our workforce in Leesburg by 96 full-time employees no later than by December 31, 2017. As a result of these commitments, we have recorded a long-term liability on our balance sheet of $790 until such conditions are met. Intellectual Property In the normal course of business, we enter into agreements to obtain the rights to certain intellectual property. These agreements may require an up-front payment, milestone payments and/or royalties. Typically, we have certain rights to cancel these agreements, with notice, without additional payments due other than the amount due at the time of cancellation. As of June 30, 2015 , the aggregate amount of these future payments, assuming achievement of applicable milestones and non-cancellation, was $ 1,495 over a period not less than five years. Royalties ranging from 2% to 10% of net sales may be due on the sales of related products. Some of the agreements contain minimum annual royalty amounts. In November 2011, we entered into an agreement to purchase certain proprietary technology which could require us to make additional aggregate payments of up to $ 13,350 should certain milestones be met, including milestones related to regulatory applications and approvals. Cumulative payments under this agreement totaled $ 100 through June 30, 2015 . In addition, milestone payments of $ 500 , $ 2,000 and $ 4,000 are due upon the achievement of net sales of related products of $ 10,000 , $ 25,000 and $ 50,000 , respectively. A royalty payment of 7% of net sales of related products may be due until such sales reaches $ 20,000 . The product related to this agreement has not yet been commercialized. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights, as well as, improper hiring practices. We are not aware of any pending or threatened legal proceeding against us that would have a material adverse effect on our business, operating results or financial condition. However, we are a party in multiple legal actions involving claimants seeking various remedies, including monetary damages, and none of the outcomes are certain or entirely within our control.

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES In connection with the Merger, we and our subsidiary K2M Inc. entered into a management agreement with our major stockholder. Fees paid for such agreement totaled $ 0 and $ 110 for the three months ended June 30, 2015 and 2014 , respectively and $ 0 and $ 373 for the six months ended June 30, 2015 and 2014 , respectively and are reflected in general and administrative expense in our condensed consolidated statements of operations. The management agreement was terminated in May 2014 following our IPO. In connection with the second public offering completed on February 2, 2015, certain stockholders granted the underwriters an option to purchase from such selling shareholders additional shares of common stock at the public offering price, less underwriting discounts. On February 12, 2015, the underwriters exercised this option and purchased 906,748 shares of common stock from selling shareholders at a price of $ 18.75 per share before underwriting discounts. We did not receive any proceeds from the sale of these shares.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The provision for income taxes for the three and six months ended June 30, 2015 and 2014 includes both domestic and foreign income taxes at applicable statutory rates adjusted for permanent differences and valuation allowances. For the three months ended June 30, 2015 and 2014 , the income tax expense was $ 19 and $ 21 , resulting in an effective tax rate of (0.3)% and (0.1)% , respectively. For the six months ended June 30, 2015 and 2014 , income tax expense was $ 42 and $ 45 , resulting in an effective tax rate of (0.2)% and (0.1)% , respectively. The effective tax rate differs from the statutory rate due to permanent differences, an increase to the valuation allowance and foreign tax rate differentials.

NET LOSS PER SHARE

NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NET LOSS PER SHARE The following table sets forth the computation of basic and diluted loss per share attributable to our common stockholders: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Net loss per common share: Net loss $ (6,222 ) $ (17,683 ) $ (20,507 ) $ (32,430 ) Less: accretion and adjustment of Series A Preferred and Series B Preferred — 8,059 — 6,879 Net loss attributable to common stockholders $ (6,222 ) $ (9,624 ) $ (20,507 ) $ (25,551 ) Basic and diluted loss per common share Basic and diluted weighted average common shares outstanding 39,836,509 30,441,034 39,291,183 26,504,068 Basic and diluted loss per common share $ (0.16 ) $ (0.32 ) $ (0.52 ) $ (0.96 ) Diluted loss per share for the three months ended June 30, 2015 and 2014 does not reflect the following weighted average potential common shares, as the effect would be antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock options 3,576,664 4,429,960 3,576,664 4,429,960 Restricted stock units 414,001 765,023 414,001 765,023

SEGMENT AND GEOGRAPHICAL CONCEN

SEGMENT AND GEOGRAPHICAL CONCENTRATION	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHICAL CONCENTRATION	SEGMENT AND GEOGRAPHICAL CONCENTRATION Operating segments are defined as components of an enterprise for which separate discrete financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We manage the business globally within one reporting segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Products are sold principally in the United States. International revenue represented 26.5% and 28.3% of total revenue for the three and six months ended June 30, 2015 ; however, revenue earned in any individual foreign country is below 10% of our consolidated revenue. The following table represents total revenue by geographic area, based on the location of the customer: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 United States $ 41,434 $ 33,217 $ 76,596 $ 62,982 International 14,920 14,271 30,182 26,757 Total $ 56,354 $ 47,488 $ 106,778 $ 89,739 We classify sales within the United States into three categories: complex spine pathologies, minimally invasive procedures and degenerative and other conditions. A significant portion of our international revenue is derived from our distributor partners who do not report their product usage at the surgeon or hospital level, which prevents us from providing a specific breakdown for our international revenue among our three product categories. These sales transactions are settled when we ship the product to the distributor. The following table represents domestic revenue by procedure category: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Complex spine $ 17,131 $ 13,858 $ 31,352 $ 25,788 Minimally invasive 6,914 5,141 12,723 9,880 Degenerative 17,389 14,218 32,521 27,314 41,434 33,217 76,596 62,982 International 14,920 14,271 30,182 26,757 Total $ 56,354 $ 47,488 $ 106,778 $ 89,739

SUBSEQUENT EVENTS (Notes)

SUBSEQUENT EVENTS (Notes)	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS On July 13, 2015, we completed an additional public offering of 4,500,000 shares of our common stock at a price to the public of $ 22.60 per share. We sold 750,000 shares of common stock in the offering and selling stockholders sold 3,750,000 shares of common stock. We received net proceeds from the offering of approximately $ 16,300 after deducting the underwriting discount and estimated offering costs. We did not receive any proceeds from shares of common stock sold by the selling stockholders. The proceeds of the primary portion of the additional public offering will be used by us for working capital and general corporate purposes, which is expected to include the expansion of our global distribution network and the purchase of inventory to support sales efforts. In addition, use of proceeds may also include the acquisition of or investment in complementary products, technologies or businesses. In connection with this offering, we and certain selling stockholders granted the underwriters an option to purchase an additional 675,000 shares of our common stock at the public offering price, less underwriting discounts. On July 17, 2015, the underwriters exercised this option and purchased 112,500 shares offered by us and 562,500 shares of common stock offered by the selling stockholders, at the public offering price of $ 22.60 per share. We received net proceeds of approximately $ 2,500 after deducting underwriting discounts and estimated offering costs. We did not receive any proceeds from shares of common stock sold by the selling stockholders.

GENERAL AND SUMMARY OF SIGNIF22

GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States or US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Net Loss per Share	Net Loss per Share Basic net loss per common share is determined by dividing the net loss allocable to common stockholders by the weighted average number of common shares outstanding during the periods presented, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the net loss allocable to common stockholders by the weighted average number of shares of common stock and common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of our stock option grants and the if-converted method is used to determine the dilutive effect of our Series A redeemable convertible preferred stock or Series A Preferred and Series B redeemable convertible preferred stock or Series B Preferred, until their conversion into common stock in May 2014. The weighted average shares used to calculate both basic and diluted loss per share are the same because common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive.
Foreign Currency Translation and Other Comprehensive Loss	Foreign Currency Translation and Other Comprehensive Loss The account balances of foreign subsidiaries are translated into U.S. dollars using exchange rates for assets and liabilities at the balance sheet date and average prevailing exchange rates for the period for revenue and expense accounts. Adjustments resulting from translation are included in other comprehensive income (loss), which is our only component of accumulated other comprehensive loss. Remeasurement gains and losses from foreign currency transactions are included in the consolidated statements of operations in the period in which they occur.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We qualify as an “emerging growth company” (EGC) pursuant to the provisions of the JOBS Act and elected to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act which permits EGCs to defer compliance with new or revised accounting standards (the EGC extension) until non-issuers are required to comply with such standards. Accordingly, so long as we continue to qualify as an EGC, we will not have to adopt or comply with new accounting standards until non-issuers are required to comply with such standards. In May 2014, the Financial Accounting Standards Board, or FASB amended the existing accounting standards for revenue recognition. The amendments are based on the principle that revenue should be recognized to depict the transfer of goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In July 2015, the FASB confirmed the deferral of the effective date by one year for public entities, other than EGCs that have elected the EGC extension. The guidance will now be effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted for reporting periods beginning after December 15, 2016. EGCs that have elected the EGC extension, including us, and non-public entities will be required to comply with the guidance for annual reporting periods beginning after December 15, 2018. The amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of the initial application. We are evaluating the impact of these amendments and the transition alternatives on our consolidated financial statements. In April 2015, the FASB issued guidance to simplify the presentation of debt issuance costs by requiring them to be presented as a deduction from the corresponding debt liability, rather than reported as an asset. This will make the presentation of debt issuance costs consistent with the presentation of debt discounts and premiums. This new guidance affects only the presentation of debt issuance costs, not recognition and measurement. For public entities other than EGCs that have elected the EGC extension, the guidance will be effective for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. For all other entities, EGCs that have elected the EGC extension, including us, and non-public entities will be required to comply with the guidance on a retrospective basis for fiscal years beginning after December 15, 2015, and interim periods within the fiscal years beginning after December 15, 2016. Although adoption of this new guidance may impact how such items are classified on our balance sheet, we do not anticipate that the adoption of this guidance will have a material impact on our financial position, results of operations or cash flows. There will be no changes to the presentations of our other consolidated financial statements. In July 2015, the FASB issued authoritative guidance to simplify the subsequent measurement of inventory. Under this new standard, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public entities other than EGCs that have elected the EGC extension, the guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. For all other entities, EGCs that have elected the EGC extension, including us, and non-public entities will be required to comply with the guidance for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of this guidance.

ACCOUNTS RECEIVABLE - (Tables)

ACCOUNTS RECEIVABLE - (Tables)	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Schedule of Accounts Receivable	The following table summarizes the accounts receivables, net of allowances: June 30, December 31, Accounts receivable $ 44,046 $ 36,431 Allowances (2,719 ) (2,494 ) Accounts receivable, net $ 41,327 $ 33,937

INVENTORY - (Tables)

INVENTORY - (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Current Inventory	The following table summarizes the inventory, net of allowance: June 30, December 31, Finished goods $ 82,767 $ 78,331 Inventory allowances (27,081 ) (25,714 ) Inventory, net $ 55,686 $ 52,617

PREPAID AND OTHER CURRENT ASS25

PREPAID AND OTHER CURRENT ASSETS (Tables)	6 Months Ended
	Jun. 30, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	The following table summarizes prepaid expenses and other current assets: June 30, December 31, Restricted cash $ 6,669 $ — Prepaid expenses 2,753 2,385 Other 2,067 1,526 Total $ 11,489 $ 3,911

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS - (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	Goodwill and intangible assets comprise the following: June 30, 2015 Estimated Useful Lives Gross Accumulated Amortization Net Goodwill — $ 121,814 $ — $ 121,814 Indefinite-lived intangible assets: Trademarks — 12,900 — 12,900 In-process research and development — 900 — 900 Other — 278 — 278 Subtotal 14,078 — 14,078 Subject to amortization Developed technology 4 - 6 years 62,000 (49,351 ) 12,649 Licensed technology 4 - 6 years 52,600 (52,250 ) 350 Customer relationships 4 - 7 years 29,700 (20,684 ) 9,016 Patents and other 2 - 17 years 1,801 (1,071 ) 730 Subtotal 146,101 (123,356 ) 22,745 Total $ 281,993 $ (123,356 ) $ 158,637 December 31, 2014 Estimated Useful Lives Gross Accumulated Amortization Net Goodwill — $ 121,814 $ — $ 121,814 Indefinite-lived intangible assets: Trademarks — 12,900 — 12,900 In-process research and development — 900 — 900 Other — 278 — 278 Subtotal 14,078 — 14,078 Subject to amortization Developed technology 4 - 6 years 62,000 (46,460 ) 15,540 Licensed technology 4 - 6 years 52,600 (52,175 ) 425 Customer relationships 4 - 7 years 29,700 (18,563 ) 11,137 Patents and other 2 - 17 years 1,414 (985 ) 429 Subtotal 145,714 (118,183 ) 27,531 Total $ 281,606 $ (118,183 ) $ 163,423
Schedule of Expected Amortization Expense	As of June 30, 2015 , the expected amortization expense for the remainder of 2015 and the following four years and thereafter is as follows: June 30, 2015 2015 $ 5,119 2016 10,238 2017 6,624 2018 129 2019 and thereafter 635 Total $ 22,745

OTHER ASSETS - (Tables)

OTHER ASSETS - (Tables)	6 Months Ended
	Jun. 30, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consist of the following: June 30, December 31, Surgical instruments, net $ 21,193 $ 21,392 Restricted cash 1,320 8,114 Other 462 166 Total $ 22,975 $ 29,672

ACCRUED EXPENSES - (Tables)

ACCRUED EXPENSES - (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: June 30, December 31, Accrued commissions $ 5,712 $ 4,942 Accrued royalties 2,261 2,464 Other 3,083 2,671 Total $ 11,056 $ 10,077

STOCK-BASED COMPENSATION - (Tab

STOCK-BASED COMPENSATION - (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	A summary of RSU activity during the six months ended June 30, 2015 is as follows: Unvested RSUs Unvested at December 31, 2014 765,023 Vested (351,022 ) Unvested at June 30, 2015 414,001
Schedule of stock-based compensation expense	tock-based compensation expense by financial statement line item, employees and non-employees and type of award for the respective period follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Cost of revenue $ 159 $ 105 $ 317 $ 111 Research, development, and engineering 151 121 300 143 Sales and marketing 753 436 1,471 633 General and administrative 945 720 1,821 871 $ 2,008 $ 1,382 $ 3,909 $ 1,758 Employees $ 1,904 $ 1,467 $ 3,731 $ 1,737 Non-employees 104 (85 ) 178 21 Total $ 2,008 $ 1,382 $ 3,909 $ 1,758 Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock options $ 573 $ 385 $ 1,110 $ 761 Restricted stock units (RSUs) 1,372 968 2,669 968 ESPP 63 29 130 29 Total $ 2,008 $ 1,382 $ 3,909 $ 1,758
Schedule of employee stock option plan activity	A summary of stock option plans activity during the six months ended June 30, 2015 is as follows: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2014 4,277,229 $ 9.55 5.83 $ 48,418 Granted 88,151 21.56 Exercised (746,572 ) 7.28 Expired (2,885 ) 5.13 Forfeited (39,259 ) 13.09 Outstanding at June 30, 2015 (2) 3,576,664 $ 10.28 5.98 $ 49,128 Vested or expected to vest: At June 30, 2015 (3) 3,246,834 $ 10.09 5.89 $ 45,221 Vested: At June 30, 2015 1,836,501 $ 9.10 4.98 $ 41,440 (1) Calculated using the estimated per-share fair market value of our common stock on June 30, 2015 and December 31, 2014 , which was $ 24.02 , and $ 20.87 , respectively. (2) The total includes 995,995 unvested performance-based options at June 30, 2015 . (3) Outstanding options, net of forfeiture rate.

NET LOSS PER SHARE - (Tables)

NET LOSS PER SHARE - (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted loss per share attributable to our common stockholders: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Net loss per common share: Net loss $ (6,222 ) $ (17,683 ) $ (20,507 ) $ (32,430 ) Less: accretion and adjustment of Series A Preferred and Series B Preferred — 8,059 — 6,879 Net loss attributable to common stockholders $ (6,222 ) $ (9,624 ) $ (20,507 ) $ (25,551 ) Basic and diluted loss per common share Basic and diluted weighted average common shares outstanding 39,836,509 30,441,034 39,291,183 26,504,068 Basic and diluted loss per common share $ (0.16 ) $ (0.32 ) $ (0.52 ) $ (0.96 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Diluted loss per share for the three months ended June 30, 2015 and 2014 does not reflect the following weighted average potential common shares, as the effect would be antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Stock options 3,576,664 4,429,960 3,576,664 4,429,960 Restricted stock units 414,001 765,023 414,001 765,023

SEGMENT AND GEOGRAPHICAL CONC31

SEGMENT AND GEOGRAPHICAL CONCENTRATION - (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of Revenue by Geographic Area	The following table represents total revenue by geographic area, based on the location of the customer: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 United States $ 41,434 $ 33,217 $ 76,596 $ 62,982 International 14,920 14,271 30,182 26,757 Total $ 56,354 $ 47,488 $ 106,778 $ 89,739
Schedule of Revenue by Products	The following table represents domestic revenue by procedure category: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Complex spine $ 17,131 $ 13,858 $ 31,352 $ 25,788 Minimally invasive 6,914 5,141 12,723 9,880 Degenerative 17,389 14,218 32,521 27,314 41,434 33,217 76,596 62,982 International 14,920 14,271 30,182 26,757 Total $ 56,354 $ 47,488 $ 106,778 $ 89,739

GENERAL AND SUMMARY OF SIGNIF32

GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 12, 2015	Feb. 02, 2015	Jun. 30, 2015	Jun. 30, 2014
Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, Shares Held by Company and Shareholders (in share)		6,044,990
Share Price (in usd per share)		$ 18.75
Stock issued during the period (in shares)		2,044,990
Stock Issued During Period, Shares, Shares Held by Shareholders (in shares)		4,000,000
Proceeds from Issuance of Common Stock		$ 35,400	$ 35,927	$ 123,456
Underwriters [Member]
Significant Accounting Policies [Line Items]
Share Price (in usd per share)	$ 18.75
Stock Issued During Period, Shares, Issued for Services (in shares)	906,748

ACCOUNTS RECEIVABLE - (Details)

ACCOUNTS RECEIVABLE - (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Receivables [Abstract]
Accounts receivable	$ 44,046	$ 36,431
Allowances	(2,719)	(2,494)
Accounts receivable, net	$ 41,327	$ 33,937

INVENTORY - (Details)

INVENTORY - (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Finished goods	$ 82,767	$ 78,331
Inventory allowances	(27,081)	(25,714)
Inventory, net	55,686	52,617
Surgical and Medical Instruments [Member]
Inventory [Line Items]
Inventory, net	$ 8,401	$ 8,491

PREPAID AND OTHER CURRENT ASS35

PREPAID AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Restricted cash	$ 6,669	$ 0
Prepaid expenses	2,753	2,385
Other	2,067	1,526
Total	$ 11,489	$ 3,911

GOODWILL AND INTANGIBLE ASSET36

GOODWILL AND INTANGIBLE ASSETS - (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Schedule of Intangible Asset by Major Class [Line Items]
Goodwill	$ 121,814		$ 121,814		$ 121,814
Indefinite-lived intangible assets	14,078		14,078		14,078
Subject to amortization, Gross	146,101		146,101		145,714
Accumulated Amortization	(123,356)		(123,356)		(118,183)
Total	22,745		22,745		27,531
Intangible Assets, Gross	281,993		281,993		281,606
Intangible Assets, Net	158,637		158,637		163,423
Amortization expense	2,551	$ 7,541	5,173	$ 15,092
Developed Technology Rights [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Subject to amortization, Gross	62,000		62,000		62,000
Accumulated Amortization	(49,351)		(49,351)		(46,460)
Total	12,649		12,649		15,540
Licensed technology [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Subject to amortization, Gross	52,600		52,600		52,600
Accumulated Amortization	(52,250)		(52,250)		(52,175)
Total	350		350		425
Customer Relationships [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Subject to amortization, Gross	29,700		29,700		29,700
Accumulated Amortization	(20,684)		(20,684)		(18,563)
Total	9,016		9,016		11,137
Patents and Other [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Subject to amortization, Gross	1,801		1,801		1,414
Accumulated Amortization	(1,071)		(1,071)		(985)
Total	730		730		429
Trademarks [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Indefinite-lived intangible assets	12,900		12,900		12,900
In-process research and development [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Indefinite-lived intangible assets	900		900		900
Other [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Indefinite-lived intangible assets	$ 278		$ 278		$ 278
Minimum [Member] | Developed Technology Rights [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			4 years	4 years
Minimum [Member] | Licensed technology [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			4 years	4 years
Minimum [Member] | Customer Relationships [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			4 years	4 years
Minimum [Member] | Patents and Other [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			2 years	2 years
Maximum [Member] | Developed Technology Rights [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			6 years	6 years
Maximum [Member] | Licensed technology [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			6 years	6 years
Maximum [Member] | Customer Relationships [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			7 years	7 years
Maximum [Member] | Patents and Other [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Estimated Useful Lives			17 years	17 years

GOODWILL AND INTANGIBLE ASSET37

GOODWILL AND INTANGIBLE ASSETS Schedule of Expected Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 2,551	$ 7,541	$ 5,173	$ 15,092
2,015	5,119		5,119
2,016	10,238		10,238
2,017	6,624		6,624
2,018	129		129
2019 and thereafter	635		635
Total	$ 22,745		$ 22,745		$ 27,531

OTHER ASSETS - (Details)

OTHER ASSETS - (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Surgical instruments, net	$ 21,193		$ 21,193		$ 21,392
Deposits Assets, Noncurrent	1,320		1,320		8,114
Other	462		462		166
Total	22,975		22,975		29,672
Surgical instruments accumulated amortization	23,118		23,118		18,610
Amortization expense	2,229	$ 1,464	4,384	$ 2,772
Escrow Deposits [Member] | Other Assets [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted Cash and Cash Equivalents	6,700		6,700
Demand Deposits [Member] | Other Assets [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted Cash and Cash Equivalents	$ 1,320		$ 1,320		$ 1,447

ACCRUED EXPENSES - (Details)

ACCRUED EXPENSES - (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued commissions	$ 5,712	$ 4,942
Accrued royalties	2,261	2,464
Other	3,083	2,671
Total	$ 11,056	$ 10,077

STOCK-BASED COMPENSATION - Allo

STOCK-BASED COMPENSATION - Allocation of Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$ 2,008	$ 1,382	$ 3,909	$ 1,758
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	159	105	317	111
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	151	121	300	143
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	753	436	1,471	633
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	945	720	1,821	871
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	1,904	1,467	3,731	1,737
Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$ 104	$ (85)	$ 178	$ 21

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		$ 2,008	$ 1,382	$ 3,909	$ 1,758
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding Beginning Balance, Shares				4,277,229
Granted, Shares				88,151
Exercised, Shares				(746,572)
Expired, Shares				(2,885)
Forfeited, Shares				(39,259)
Outstanding Ending Balance, Shares	[1]	3,576,664		3,576,664
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning, Weighted-Average Exercise Price (in usd per share)				$ 9.55
Granted, Weighted-Average Exercise Price (in usd per share)				21.56
Exercised, Weighted-Average Exercise Price (in usd per share)				7.28
Expired, Weighted-Average Exercise Price (in usd per share)				5.13
Forfeited, Weighted-Average Exercise Price (in usd per share)				13.09
Ending, Weighted-Average Exercise Price (in usd per share)		$ 10.28		$ 10.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2				5 years 11 months 23 days	5 years 9 months 29 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2				5 years 11 months 23 days	5 years 9 months 29 days
Outstanding, Aggregate Intrinsic Value	[2]			$ 48,418
Outstanding, Aggregate Intrinsic Value	[2]	$ 49,128		$ 49,128
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Vested or expected to vest, shares	[3]	3,246,834		3,246,834
Vested or expected to vest, Weighted-Average Exercise Price (in usd per share)		$ 10.09		$ 10.09
Vested or expected to vest, Weighted-Average Remaining Contractual Term				5 years 10 months 20 days
Vested or expected to vest, Aggregate Intrinsic Value	[2]	$ 45,221		$ 45,221
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested [Abstract]
Vested, shares		1,836,501		1,836,501
Vested, Weighted-Average Exercise Price (in usd per share)		$ 9.10		$ 9.10
Vested, Weighted-Average Remaining Contractual Term				4 years 11 months 23 days
Vested, Aggregate Intrinsic Value	[2]	$ 41,440		$ 41,440
Fair value valuation, estimated fair market value of stock (in dollars per share)		$ 24.02		$ 24.02		$ 20.87
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding Ending Balance, Shares		995,995		995,995
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		$ 573	385	$ 1,110	$ 761
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		159	105	317	111
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		151	121	300	143
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		753	436	1,471	633
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		945	720	1,821	871
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		1,904	1,467	3,731	1,737
Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense		$ 104	$ (85)	$ 178	$ 21
[1]	The total includes 995,995 unvested performance-based options at June 30, 2015.
[2]	Calculated using the estimated per-share fair market value of our common stock on June 30, 2015 and December 31, 2014, which was $24.02, and $20.87, respectively.
[3]	Outstanding options, net of forfeiture rate.

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details)	6 Months Ended
	Jun. 30, 2015planshares	Dec. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Plans | plan	4
Employee Stock Purchase Plans, Shares Reserved for Future Issuance (in shares)	1,374,208
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	414,001	765,023
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	155,494,000

STOCK-BASED COMPENSATION Share-

STOCK-BASED COMPENSATION Share-Based Compensation Related to Restricted (Details) - Restricted Stock Units (RSUs) [Member] - shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	414,001	765,023
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(351,022)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	155,494,000

STOCK-BASED COMPENSATION Stock

STOCK-BASED COMPENSATION Stock option award type (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$ 2,008	$ 1,382	$ 3,909	$ 1,758
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	1,372	968	2,669	968
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	573	385	1,110	761
Employee Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$ 63	$ 29	$ 130	$ 29

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - (Details)	1 Months Ended	6 Months Ended
	Nov. 30, 2011USD ($)	Jun. 30, 2015USD ($)Position	Jun. 30, 2014USD ($)
Long-term Purchase Commitment [Line Items]
Revenue from Grants		$ 790,000
Grant, Terms and Conditions, Required Increase in Workforce by Specified Date | Position		96
Unearned Grants		$ 790,000
Initial payment to acquire proprietary technology		388,000	$ 19,000
Licensed technology [Member]
Long-term Purchase Commitment [Line Items]
Other Commitment		$ 1,495,000
Minimum contractual term		5 years
Licensed technology [Member] | Minimum [Member]
Long-term Purchase Commitment [Line Items]
Future maximum royalty payments		2.00%
Licensed technology [Member] | Maximum [Member]
Long-term Purchase Commitment [Line Items]
Future maximum royalty payments		10.00%
In Process Research and Development [Member]
Long-term Purchase Commitment [Line Items]
Future maximum royalty payments	7.00%
Initial payment to acquire proprietary technology		$ 100,000
Milestone payment one	$ 500,000
Milestone payment two	2,000,000
Milestone payment three	4,000,000
Milestone for milestone payment one	10,000,000
Milestone for milestone payment two	25,000,000
Milestone for milestone payment three	50,000,000
Milestone for ending royalty payments, cumulative sales	20,000,000
In Process Research and Development [Member] | Maximum [Member]
Long-term Purchase Commitment [Line Items]
Other Commitment	$ 13,350,000

RELATED PARTIES - (Details)

RELATED PARTIES - (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 12, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Feb. 02, 2015
Related Party Transaction [Line Items]
Stock Issued During Period, Value, Issued for Services (in usd per share)						$ 18.75
Major Stockholder [Member] | Related Party Transaction, Management Service Fee [Member]
Related Party Transaction [Line Items]
General and administrative		$ 0	$ 110	$ 0	$ 373
Underwriters [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services (in shares)	906,748
Stock Issued During Period, Value, Issued for Services (in usd per share)	$ 18.75

INCOME TAXES - (Details)

INCOME TAXES - (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 19	$ 21	$ 42	$ 45
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent	0.00%	0.00%	0.00%	0.00%

NET LOSS PER SHARE - (Details)

NET LOSS PER SHARE - (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Net loss	$ (6,222)	$ (17,683)	$ (20,507)	$ (32,430)
Less: accretion and adjustment of Series A Preferred and Series B Preferred	0		0
Less: accretion and adjustment of Series A Preferred and Series B Preferred		8,059		6,879
Net loss attributable to stockholders	$ (6,222)	$ (9,624)	$ (20,507)	$ (25,551)
Basic and diluted weighted average common shares outstanding	39,836,509	30,441,034	39,291,183	26,504,068
Basic and diluted loss per common share (in dollars per share)	$ (0.16)	$ (0.32)	$ (0.52)	$ (0.96)

NET LOSS PER SHARE - Antidiluti

NET LOSS PER SHARE - Antidilutive Shares (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Earnings Per Share (in shares)	3,576,664	4,429,960	3,576,664	4,429,960
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Earnings Per Share (in shares)	414,001	765,023	414,001	765,023

SEGMENT AND GEOGRAPHICAL CONC50

SEGMENT AND GEOGRAPHICAL CONCENTRATION - Narrative (Details) - Jun. 30, 2015 - Segment	Total	Total
Segment Reporting Information [Line Items]
Number of reportable segments		1
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | International [Member]
Segment Reporting Information [Line Items]
International revenue as a percentage of total revenue	0.00%	0.00%
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | United States [Member]
Segment Reporting Information [Line Items]
International revenue as a percentage of total revenue		10.00%

SEGMENT AND GEOGRAPHICAL CONC51

SEGMENT AND GEOGRAPHICAL CONCENTRATION - Revenues by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 56,354	$ 47,488	$ 106,778	$ 89,739
Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Revenue	56,354	47,488	106,778	89,739
United States [Member]
Segment Reporting Information [Line Items]
Revenue	41,434	33,217	76,596	62,982
United States [Member] | Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Revenue	41,434	33,217	76,596	62,982
International [Member]
Segment Reporting Information [Line Items]
Revenue	14,920	14,271	30,182	26,757
International [Member] | Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Revenue	$ 14,920	$ 14,271	$ 30,182	$ 26,757

SEGMENT AND GEOGRAPHICAL CONC52

SEGMENT AND GEOGRAPHICAL CONCENTRATION - Revenues by Product (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue from External Customer [Line Items]
Revenue	$ 56,354	$ 47,488	$ 106,778	$ 89,739
United States [Member]
Revenue from External Customer [Line Items]
Revenue	41,434	33,217	76,596	62,982
United States [Member] | Complex Spine [Member]
Revenue from External Customer [Line Items]
Revenue	17,131	13,858	31,352	25,788
United States [Member] | Minimally Invasive [Member]
Revenue from External Customer [Line Items]
Revenue	6,914	5,141	12,723	9,880
United States [Member] | Degenerative [Member]
Revenue from External Customer [Line Items]
Revenue	17,389	14,218	32,521	27,314
International [Member]
Revenue from External Customer [Line Items]
Revenue	$ 14,920	$ 14,271	$ 30,182	$ 26,757

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 17, 2015	Jul. 13, 2015	Feb. 12, 2015	Feb. 02, 2015	Jun. 30, 2015	Jun. 30, 2014
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Shares Held by Company and Shareholders (in share)				6,044,990
Share Price (in usd per share)				$ 18.75
Issuances of common stock (in shares)				2,044,990
Proceeds from issuances of common stock, net of issuance costs				$ 35,400	$ 35,927	$ 123,456
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Shares Held by Company and Shareholders (in share)		4,500,000
Share Price (in usd per share)		$ 22.60
Issuances of common stock (in shares)		750,000
Proceeds from issuances of common stock, net of issuance costs	$ 2,500	$ 16,300
Underwriters [Member]
Subsequent Event [Line Items]
Share Price (in usd per share)			$ 18.75
Stock Issued During Period, Shares, Issued for Services (in shares)			906,748
Underwriters [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Shares Held by Company and Shareholders (in share)	675,000
Share Price (in usd per share)	$ 22.60
Stock Issued During Period, Shares, Issued for Services (in shares)	112,500
Investor [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Issuances of common stock (in shares)		3,750,000
Investor [Member] | Underwriters [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services (in shares)	562,500